These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27482884)

  • 1. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
    Xu J; Pham CG; Albanese SK; Dong Y; Oyama T; Lee CH; Rodrik-Outmezguine V; Yao Z; Han S; Chen D; Parton DL; Chodera JD; Rosen N; Cheng EH; Hsieh JJ
    J Clin Invest; 2016 Sep; 126(9):3526-40. PubMed ID: 27482884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif.
    Land SC; Tee AR
    J Biol Chem; 2007 Jul; 282(28):20534-43. PubMed ID: 17502379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
    Grabiner BC; Nardi V; Birsoy K; Possemato R; Shen K; Sinha S; Jordan A; Beck AH; Sabatini DM
    Cancer Discov; 2014 May; 4(5):554-63. PubMed ID: 24631838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
    Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
    Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
    Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unconventional mechanism of action and resistance to rapalogs in renal cancer.
    Yang J; Butti R; Cohn S; Toffessi-Tcheuyap V; Mal A; Nguyen M; Stevens C; Christie A; Mishra A; Ma Y; Kim J; Abraham R; Kapur P; Hammer RE; Brugarolas J
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2310793121. PubMed ID: 38861592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
    Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
    Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.
    Liu XL; Zhang GM; Huang SS; Shi WH; Ye LX; Ren ZL; Zhang JJ; Liu SW; Yu L; Li YL
    Acta Pharmacol Sin; 2022 Sep; 43(9):2397-2409. PubMed ID: 35165399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
    Gemmill RM; Zhou M; Costa L; Korch C; Bukowski RM; Drabkin HA
    Br J Cancer; 2005 Jun; 92(12):2266-77. PubMed ID: 15956968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma.
    Ganner A; Gehrke C; Klein M; Thegtmeier L; Matulenski T; Wingendorf L; Wang L; Pilz F; Greidl L; Meid L; Kotsis F; Walz G; Frew IJ; Neumann-Haefelin E
    Sci Rep; 2021 Jul; 11(1):14827. PubMed ID: 34290272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.
    Sutphin PD; Chan DA; Li JM; Turcotte S; Krieg AJ; Giaccia AJ
    Cancer Res; 2007 Jun; 67(12):5896-905. PubMed ID: 17575159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
    Sakamoto H; Yamasaki T; Sumiyoshi T; Takeda M; Shibasaki N; Utsunomiya N; Arakaki R; Akamatsu S; Kobayashi T; Inoue T; Kamba T; Nakamura E; Ogawa O
    Cancer Med; 2021 Jan; 10(1):119-134. PubMed ID: 33107222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
    Roldán-Romero JM; Valdivia C; Santos M; Lanillos J; Maroto P; Anguera G; Calsina B; Martinez-Montes A; Monteagudo M; Mellid S; Leandro-García LJ; Montero-Conde C; Cascón A; Roncador G; Coloma J; Robledo M; Rodriguez-Antona C
    Int J Cancer; 2023 Sep; 153(6):1300-1312. PubMed ID: 37260183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
    Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
    Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein.
    Kaelin WG
    Cancer; 2009 May; 115(10 Suppl):2262-72. PubMed ID: 19402056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.